Astellas intent on CV Therapeutics despite cold shoulder
This article was originally published in Scrip
Executive Summary
Astellashas disclosed that it is pursuing the acquisition of CV Therapeuticsin a $16 per share all-cash offer, although the US firm has so far steadfastly rebuffed the proposal.